---
title: "Analyst Reiterates Buy on Vertex as Cost-Cutting, AI Focus Boost FCF Outlook; Price Target Maintained at $20"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284452443.md"
description: "Needham analyst Joshua Reilly has reiterated a Buy rating on Vertex, maintaining a price target of $20. The positive outlook is attributed to Vertex's new \"Value Creation Plan,\" which includes a focus on AI and a 9% reduction in headcount to enhance efficiency. Reilly projects that these changes will increase annual free cash flow from $70 million to approximately $90 million, despite one-time restructuring costs in FY26. He expects margins to improve and the stock to respond favorably under new CEO Chris Young."
datetime: "2026-04-28T21:25:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284452443.md)
  - [en](https://longbridge.com/en/news/284452443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284452443.md)
---

# Analyst Reiterates Buy on Vertex as Cost-Cutting, AI Focus Boost FCF Outlook; Price Target Maintained at $20

Needham analyst Joshua Reilly maintained a Buy rating on Vertex today and set a price target of $20.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Joshua Reilly has given his Buy rating due to a combination of factors tied to Vertex’s new “Value Creation Plan” and improving financial profile. The company is sharpening its focus on becoming more AI-enabled and streamlining operations, including a 9% headcount reduction, which he expects will remove prior inefficiencies and better align costs with growth.

Reilly estimates these changes should lift annual free cash flow from about $70 million to roughly $90 million, even after accounting for one-time restructuring charges in FY26. With margins set to move closer to peers and a more decisive pace of change under new CEO Chris Young, he anticipates the stock will respond positively, supporting his reiterated Buy rating and unchanged $20 price target.

### Related Stocks

- [VERX.US](https://longbridge.com/en/quote/VERX.US.md)

## Related News & Research

- [What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?](https://longbridge.com/en/news/287236369.md)
- [Is AI a bubble? It’s starting to get soapy](https://longbridge.com/en/news/286937439.md)
- [Google's latest AI flex came with Silicon Valley's new favorite word](https://longbridge.com/en/news/286951990.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)